Instrument Inactif

Autres langues Mylan Inc Nasdaq

Actions

US6285301072

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

16/09	Gilead Sciences étend ses accords de licence pour son traitement contre le VIH	MT
16/09	Gilead Sciences élargit ses accords de licence pour le Lénacapavir expérimental

Autres langues

16/09	Gilead Sciences Expands Licensing Agreements for HIV Treatment
16/09	Viatris Announces Approval Of WAKIX In Japan For Narcolepsy And Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
16/09	Viatris Says Wakix Wins Japan Approval for Narcolepsy, Obstructive Sleep Apnea
16/09	Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
10/09	Shell sells Rhode Island power plant to Constellation Energy for $715 million, acquires Hunlock Creek
08/09	Roivant's experimental lung disease drug meets goals in mid-stage study
03/09	US FDA is working with manufacturers to boost estrogen patch supply amid access concerns
28/08	Shield Therapeutics to Take Over US Commercialization of ACCRUFeR
27/08	Shield Therapeutics takes full control of ferric maltol product in US
25/08	Tialis shares slip on first-half revenue decline but loss narrows
24/08	UPC Paris LD Holds Onto Jurisdiction Finding PI And Decision On The Merits Applications (And Revocation + DNI) Are Not The Same Cause Of Action
19/08	Viatris' China Policy Concerns Overstated, UBS Says
07/08	Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
06/08	Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022.
06/08	Harrow, Inc. entered into an Asset Purchase Agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc. for $100 million.
06/08	Viatris Announces Quarterly Dividend
06/08	Viatris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Viatris Inc. Raises Earnings Guidance for the Fiscal Year 2026
06/08	Viatris' Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance
06/08	(VTRS) Viatris Expects 2026 Revenue Range $14.55B - $14.95B, vs. FactSet Est of $14.79B
06/08	(VTRS) Viatris Expects 2026 Adjusted EPS Range $2.45 - $2.59, vs. FactSet Est of $2.45
06/08	Viatris raises annual profit forecast on branded drug strength
06/08	Earnings Flash (VTRS) Viatris Inc. Reports Q2 Revenue $3.76B, vs. FactSet Est of $3.68B
06/08	Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60
06/08	Viatris: Q2 Earnings Snapshot